US 12,168,083 B2
Method for producing a fibrin-based bioartificial, primarily acellular construct, and the construct itself
Thomas Aper, Hannover (DE); Mathias Wilhelmi, Isernhagen (DE); and Axel Haverich, Hannover (DE)
Assigned to GOTTFRIED WILHELM LEIBNIZ UNIVERSITÄT HANNOVER, Hannover (DE)
Filed by MEDIZINISCHE HOCHSCHULE HANNOVER, Hannover (DE)
Filed on Jun. 14, 2021, as Appl. No. 17/346,872.
Application 17/346,872 is a division of application No. 15/740,247, granted, now 11,065,366, previously published as PCT/EP2016/066135, filed on Jul. 7, 2016.
Claims priority of application No. 10 2015 111 126.8 (DE), filed on Jul. 9, 2015.
Prior Publication US 2022/0072197 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61L 27/26 (2006.01); A61L 27/22 (2006.01); A61L 27/50 (2006.01); A61L 27/54 (2006.01); A61L 31/04 (2006.01); A61L 33/00 (2006.01); A61L 33/08 (2006.01)
CPC A61L 27/26 (2013.01) [A61L 27/225 (2013.01); A61L 27/507 (2013.01); A61L 27/54 (2013.01); A61L 31/046 (2013.01); A61L 33/0011 (2013.01); A61L 33/08 (2013.01); A61L 2300/236 (2013.01); A61L 2300/252 (2013.01); A61L 2300/254 (2013.01); A61L 2300/418 (2013.01); A61L 2300/42 (2013.01); A61L 2420/02 (2013.01); A61L 2430/06 (2013.01); A61L 2430/20 (2013.01)] 11 Claims
 
1. A method for producing a fibrin-based bioartificial and acellular planar construct, comprising:
provision of a fibrinogen-containing and cell-free composition;
provision of a thrombin-containing and cell-free composition;
application of the fibrinogen-containing cell-free and the thrombin-containing cell-free compositions to a mould as an applied layer of a mixture of compositions;
pressurization of the mixture of compositions applied to the mould at least until the fibrin formation is essentially completed; and
removal of the fibrin-based acellular bioartificial planar construct from the mould,
wherein pressure is applied in a planar manner to the compositions applied to the mould,
wherein the pressurization takes place at a relative pressure of at least 1 bar,
wherein the fibrin-based acellular bioartificial construct has at least a portion with a wall thickness of at least 1 mm, and
wherein the mould has through holes.